Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

2023803 citationsJournal Articlegreen Open Access

Authors

Steven E. Nissen · Cleveland Clinic

A. Michael Lincoff · Cleveland Clinic

Danielle M. Brennan · Cleveland Clinic

Kausik K. Ray · Amsterdam UMC Location University of Amsterdam

Denise Mason · Cleveland Clinic

John J.P. Kastelein · Amsterdam UMC Location University of Amsterdam

Paul D. Thompson

Abstract

Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).

Topics & Keywords

Lipoproteins and Cardiovascular Health Systemic Lupus Erythematosus Research Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 15, pp. 1353-1364

DOI: 10.1056/nejmoa2215024

Field-Weighted Citation Impact: 252.81